INTRODUCTION
A supernumerary marker chromosome (SMC) is defined as a structurally abnormal chromosome that occurs in addition to the 46 normal chromosomes, and that cannot be unambiguously identified or characterized by conventional banding cytogenetics [1] . The prevalence of SMC is 0.4-1.5/1,000 in prenatal diagnosis and 0.66/1,000 in newborns, with a higher frequency in mentally delayed populations (3.27/1,000) [2] . SMCs are associated with phenotypic heterogeneity and even found in phenotypically normal individuals. When an SMC is diagnosed, predicting the risk associated with an abnormal phenotype remains difficult, especially for de novo cases [3] . The clinical variability among SMCs may be attributed to their size, the presence of euchromatic material, the degree of mosaicism, and/or the uniparental disomy. Therefore, the precise characterization of SMCs is essential in order to perform genotype-phenotype correlation and predict the prognosis [4, 5] . Here, we present a case of SMC that was proved to be der(18)t(2;18)(p23.1;q11.1) by array comparative genomic hybridization (aCGH). The patient had typical phenotype characteristics of partial trisomy 2p23-pter syndrome.
To our knowledge, this is the first report of a combined partial trisomy 2p and trisomy 18p due to an SMC. 
CASE REPORT

Clinical features
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Partial trisomy 2p is a rare but relatively well-defined syndrome with distinctive clinical features, including marked psychomotor delay, dysmorphic face, and congenital heart disease. The phenotype of trisomy 18p is variable, from normal appearance to moderate mental retardation. Most cases of trisomy 2p and trisomy 18p result from the inheritance of an unbalanced segregant from a balanced parental translocation or due to de novo duplication. Here, we present the first report of a combined partial trisomy 2p and trisomy 18p due to a supernumerary marker chromosome (SMC). The final karyotype of the patient was 47,XX,+der (18) 
DISCUSSION
The partial trisomy 2p syndrome is a rare constitutional aneuploidy in humans. It was first described by Francke and Jones [8] and has been reported in over 60 cases [8, 9] . Trisomy 2p could arise as a result of malsegregation of balanced parental translocation, or less frequently, due to de novo duplication or addition to another chromosome. maternal and 10% paternal inheritance [24] . Familial marker chromosomes are usually harmless if they have been inherited from a phenotypically normal parent [25] , but the clinical outcome is difficult to predict in cases with a de novo SMC. The risk for a de novo SMC to produce an abnormal phenotype has been estimated to be about 13- [28] . The aCGH technique should facilitate precise genotype-phenotype correlation and prediction of the clinical outcome [13] .
In summary, we described the first case of partial trisomy 2p23-pter and trisomy 18p due to an SMC. Partial trisomy 2p rather than trisomy 18p may be responsible for the clinical manifestations in our patient. Because a neuroblastoma is regarded as a common manifestation of trisomy 2p and our patient showed gain of MYCN gene, we recommend careful observation in such patients.
